Health News Releases

  • Today February 18
November 05, 2015 14:00
Cell Signaling Technology Announces the Release of 6 New Monoclonal Antibodies for Tumor Immunology Research.
Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of 6 new monoclonal antibodies (mAb) for tumor immunology research. This announcement was made at
November 05, 2015 13:10
Pharco Pharmaceuticals, Inc. Announces Late-Breaker Oral Presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2015
Pharco Pharmaceuticals, Inc. announced today that Gamal Esmat, M.D., Professor of Haepatology and Endemic Medicine at Cairo University and WHO viral hepatitis expert, will present advanced results of
November 05, 2015 12:10
Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
Not intended for UK-based media Merck and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanc
November 05, 2015 10:45
Singapore General Hospital and Thermo Fisher Scientific Collaborate to Identify the Prevalence of Asian-Specific Genetic Mutations in Cancer
Singapore General Hospital (SGH) and Thermo Fisher Scientific today announced the establishment of a collaborative partnership that will work to identify cancer genetic mutations linked with Asian pop
November 03, 2015 17:25
Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound
Boehringer Ingelheim today announced at the BIO-Europe® conference in Munich, Germany, the initiation of a global Phase II trial evaluating the efficacy and safety of BI 1482694 (HM61713) in patients
Institut Pasteur Korea held a press conference on November 2, 2015. Researchers addressed the curren
November 03, 2015 07:00
IPK Discusses MERS/Ebola Research Status and Korea’s Response Strategies Against Infectious Diseases
During a press conference held at Korea Press Center on November 2, 2015; Institut Pasteur Korea (IPK, CEO: Dr. Hakim Djaballah) addressed the current research status on MERS and Ebola virus infection
November 02, 2015 15:20
Multi-Stakeholder Study Reveals That Clinical Research Participation Leads to Higher Patient Engagement, Reduced Cost of Care
Quintiles (www.quintiles.com), the world’s largest provider of product development and integrated healthcare services, today published new research that reveals high levels of patient satisfaction and
November 02, 2015 14:50
Takeda Reports Results for the First Half of FY2015…Confirms Management Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502): First half results aligned with management guidance · Underlying revenue +3.8% year-to-year (reported revenue growing +6.2% to 904 billion yen
October 31, 2015 17:00
Mannatech Launches Brain-supporting Cognitate™ Supplement in Korea at Company’s Biggest Global Event
Mannatech, Incorporated (http://us.mannatech.com) (NASDAQ: MTEX, http://goo.gl/SP6Q2G), the founder of the M5M℠ (Mission 5 Million℠) Foundation (http://m5mfoundation.org), the pioneer of nutritional g
October 31, 2015 09:00
Mannatech Launches Freshden Toothpaste Containing Natural Ingredients at Global Event in Korea
Mannatech, Incorporated (http://us.mannatech.com) (NASDAQ: MTEX, http://goo.gl/SP6Q2G), the founder of the M5M℠ (Mission 5 Million℠) Foundation (http://m5mfoundation.org), the pioneer of nutritional g
October 30, 2015 16:55
Two New Clinical Studies Using Masimo Technologies Presented at the American Society of Anesthesiologists Annual Meeting
Masimo (www.masimo.com) (NASDAQ: MASI) announced today that two new studies using Masimo technologies were presented at the American Society of Anesthesiologists (ASA) annual meeting in San Diego, Cal
October 29, 2015 23:55
Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab
Boehringer Ingelheim today announced results from a Phase I study (NCT02045979, https://goo.gl/ZaRHyV) of its biosimilar candidate (BI695501) for adalimumab (AbbVie’s Humira®), that demonstrated pharm
October 29, 2015 23:50
CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
Boehringer Ingelheim today announced the presentation of several new post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 studies at the American College of CHEST Physicians Annual Meeting in Montre
October 29, 2015 14:20
Terumo BCT Completes the First Clinical Study Reducing Malaria Transmission from Whole Blood Transfusions with Pathogen Reduction Technology
In low-income countries, 69 percent of collected blood is transfused as whole blood (WB) rather than blood components.[1] However, health care professionals have had no proven method to inactivate har
October 29, 2015 13:30
Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL)
Seattle Genetics, Inc. (www.seattlegenetics.com) (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (www.takeda.com) (TSE:4502) today announced that the companies have achieved completion of tar
October 28, 2015 13:50
Masimo Announces FDA 510(k) Clearance for MightySat™ Rx Fingertip Pulse Oximeter
Masimo (NASDAQ: MASI) announced today FDA 510(k) clearance for MightySat Rx, a fingertip pulse oximeter that incorporates Masimo SET® Measure-through Motion and Low Perfusion™ technology. This Smar
October 27, 2015 14:25
1abtik ag Founded to Fight Sepsis with Novel Antibody Therapeutics
The 1abtik ag was recently founded with the sole focus to develop a game-changing antibody-based therapy for sepsis. 1abtik has now entered the financing phase for the drug development process ranging
October 27, 2015 11:55
Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today presented results from the maintenance phase of the TOUCHSTONE phase 2 clinical trial of Ozanimod, an
October 23, 2015 13:40
Quintiles and IMS Health Announce Global Collaboration to Advance the Use of Next-Generation Real-World Evidence in Late-Stage Clinical Research
Quintiles and IMS Health today announced a global strategic alliance that will advance the way biopharmaceutical companies generate real-world evidence (RWE) and apply critical insights to drive late-
October 23, 2015 12:00
Masimo & Atheer to Demonstrate Prototype of Interactive Root® Iris™ Display Powered by AiR™ Smart Glasses Platform
Masimo (NASDAQ: MASI) and Atheer announced today that they will unveil a prototype of the Root Iris display App using the Atheer AiR (Augmented interactive Reality) platform and AiR Glasses at the Ame
October 23, 2015 10:30
Asia MannaFest Sets the Tone for Mannatech’s Expansion Plans
Mannatech, Incorporated (http://us.mannatech.com) (NASDAQ: MTEX http://goo.gl/SP6Q2G), the founder of the M5M℠ (Mission 5 Million℠) Foundation (http://m5mfoundation.org), the pioneer of nutritional gl
October 20, 2015 16:40
Quintiles Names Kevin Gordon as COO, Appoints Mike McDonnell as CFO
Quintiles announced that Kevin Gordon, currently serving as Executive Vice President, Operations and Chief Financial Officer (CFO), has been promoted to Chief Operating Officer (COO) and that Michael
October 20, 2015 14:40
Adare Pharmaceuticals Appoints James Jogerst as Vice President, Corporate Development
Adare Pharmaceuticals, Inc. announced today that James (Jim) Jogerst has joined the Company as Vice President, Corporate Development. He will be based at the Company’s headquarters in Princeton, NJ.
October 20, 2015 11:50
Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session
Celgene Corporation (NASDAQ: CELG) today announced detailed results from the maintenance phase of the TOUCHSTONE phase 2 clinical trial of Ozanimod, an investigational compound, in patients with moder
October 19, 2015 18:15
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim GmbH announced the U.S. Food and Drug Administration (FDA) granted approval of Praxbind® (idarucizumab).[4] Praxbind® is indicated for patients treated with Pradaxa® (dabigatran e
25 per page50 per page75 per page100 per page